Literature DB >> 16791629

[Noninvasive and invasive bladder cancer: diagnostics and treatment].

P J Goebell1, F Vom Dorp, C Rödel, D Frohneberg, J W Thüroff, D Jocham, C Stief, S Roth, R Knüchel, K W Schmidt, I Kausch, D Zaak, C Wiesner, K Miller, R Sauer, H Rübben.   

Abstract

Therapy of superficial bladder tumors is transurethral resection (TUR), and in cases of pT1 or high-grade tumors a re-TUR is indicated. Patients with carcinoma in situ receive intravesical chemotherapy or BCG for at least 3 months. Persistent carcinoma in situ may be treated by radical cystectomy. With the provision of a functionally adequate urinary diversion, cystectomy represents an effective treatment for patients with muscle-invasive bladder cancer without metastatic spread. Regional lymph node metastases can be found in up to 15% of stage T1 disease and are present in 33% of stage T3/4 lesions. Thus, lymphadenectomy gains diagnostic and possibly also therapeutic importance. For selected patients, who cannot be treated by radical cystectomy, multimodal concepts aiming to preserve the bladder are discussed. After or prior to cystectomy systemic chemotherapy may become necessary for some patients to positively affect the course of the disease in cases of locally advanced or metastatic lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16791629     DOI: 10.1007/s00120-006-1065-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  58 in total

Review 1.  Pelvic recurrences post cystectomy: current treatment strategies.

Authors:  T G Schuster; D C Smith; J E Montie
Journal:  Semin Urol Oncol       Date:  2001-02

2.  Improved detection of recurrent bladder cancer using the Bard BTA stat Test.

Authors:  M F Sarosdy; M A Hudson; W J Ellis; M S Soloway; R deVere White; J Sheinfeld; M V Jarowenko; P F Schellhammer; E W Schervish; J V Patel; G W Chodak; D L Lamm; R D Johnson; M Henderson; G Adams; B A Blumenstein; K R Thoelke; R D Pfalzgraf; H A Murchison; S L Brunelle
Journal:  Urology       Date:  1997-09       Impact factor: 2.649

Review 3.  Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.

Authors:  William U Shipley; Anthony L Zietman; Donald S Kaufman; John J Coen; Howard M Sandler
Journal:  Semin Radiat Oncol       Date:  2005-01       Impact factor: 5.934

4.  Cytogenetic studies of carcinoma in situ of the bladder: prognostic implications.

Authors:  M Tyrkus; I Powell; W Fakr
Journal:  J Urol       Date:  1992-07       Impact factor: 7.450

5.  Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.

Authors:  R Sauer; S Birkenhake; R Kühn; C Wittekind; K M Schrott; P Martus
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-01       Impact factor: 7.038

6.  A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.

Authors:  V Poulakis; U Witzsch; R De Vries; H M Altmannsberger; M J Manyak; E Becht
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

7.  Organ-sparing treatment of advanced bladder cancer: a 10-year experience.

Authors:  J Dunst; R Sauer; K M Schrott; R Kühn; C Wittekind; A Altendorf-Hofmann
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-09-30       Impact factor: 7.038

8.  Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization.

Authors:  J Richter; L Beffa; U Wagner; P Schraml; T C Gasser; H Moch; M J Mihatsch; G Sauter
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  Long-term results of orthotopic neobladder reconstruction after radical cystectomy.

Authors:  J N Kulkarni; C S Pramesh; S Rathi; G H Pantvaidya
Journal:  BJU Int       Date:  2003-04       Impact factor: 5.588

Review 10.  Neoadjuvant chemotherapy for invasive bladder cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18
View more
  2 in total

1.  [Interdisciplinary networking for clinical and molecular questions in non-muscle invasive urothelial carcinoma of the bladder].

Authors:  S Denzinger; A Hartmann; F Hofstaedter; R Knuechel; P J Wild; D Zaak; C Stief; W F Wieland; R Stoehr; M Burger
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

2.  Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.

Authors:  Maria Lehmann; Michèle J Hoffmann; Annemarie Koch; Scott M Ulrich; Wolfgang A Schulz; Günter Niegisch
Journal:  J Exp Clin Cancer Res       Date:  2014-07-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.